Citi Maintains a 'Buy' on Myriad Genetics (MYGN); Sell-Off Overdone - Presents Buying Opportunity
Tweet Send to a Friend
Citi maintains a 'Buy' on Myriad Genetics (Nasdaq: MYGN). Price target $42.
Citi analyst says, "We believe that the negative ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Citi analyst says, "We believe that the negative ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
